Cell-based hair restoration: verify diagnosis, product and comparative evidence
Hair loss has multiple causes and established management options. A cell-related procedure should not be presented as a proven substitute without product-specific controlled evidence.
Begin with a dermatological diagnosis. Pattern hair loss, alopecia areata, scarring alopecia, telogen effluvium, medicine effects and systemic disease require different evaluation and treatment. Photography without standardisation or a marketing consultation can miss progression and contraindications.
Identify the intervention precisely: follicular units, dissociated cells, adipose preparation, platelet product, conditioned medium, exosomes or another material. Record autologous or allogeneic status, manipulation, dose, route, treatment area, schedule, manufacturer and release tests. These products are not interchangeable.
Compare with established options for the diagnosed condition, including no procedure. For studies, require a defined population, comparator, standardised global photography, blinded hair counts, patient-reported outcomes, adverse events and sufficient follow-up. A before-and-after image cannot separate treatment effect from lighting, styling, natural cycling or concurrent medicines.
Ask about collection and injection risks, infection, contamination, scarring, inflammation, immune reactions, unexpected tissue response and management of complications. Claims of follicle regeneration or permanent restoration require clinical evidence for the exact preparation, not laboratory markers or animal growth.
Request the marketing-authorisation or authorised-trial reference and independent dermatology advice. Use the ISSCR patient guide to distinguish established, investigational and unproven interventions. Availability in an aesthetic clinic does not establish a regenerative mechanism or comparative benefit.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Commercial price observations are heterogeneous and most cell-therapy uses remain investigational. Verify source scope, regulatory status and the proposed care with an independent qualified physician.